about
Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal diseaseMedication errors in chronic kidney disease: one piece in the patient safety puzzle.Remote Usability Testing and Satisfaction with a Mobile Health Medication Inquiry System in CKDAdverse safety events in chronic kidney disease: the frequency of "multiple hits"Patient-reported and actionable safety events in CKD.Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.Retinopathy and progression of CKD: The CRIC studyAssociation between retinopathy and cardiovascular disease in patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC] Study).Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology.The outcome of the urban renal patient: the importance of social factors and center effects.APOL1 risk variants, race, and progression of chronic kidney diseaseLongitudinal association of depressive symptoms with rapid kidney function decline and adverse clinical renal disease outcomes.Metabolic syndrome, components, and cardiovascular disease prevalence in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.Chronic pain and analgesic use in CKD: implications for patient safety.Hemodynamic correlates of proteinuria in chronic kidney disease.Pre-clinical myocardial metabolic alterations in chronic kidney disease.Association between Inflammation and Cardiac Geometry in Chronic Kidney Disease: Findings from the CRIC Study.Urinary sodium is a potent correlate of proteinuria: lessons from the chronic renal insufficiency cohort studyRetinopathy and the risk of cardiovascular disease in patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort study).Patient safety issues in CKD: core curriculum 2015.Salt intake and progression of chronic kidney disease: an overlooked modifiable exposure? A commentary.Chronic Renal Insufficiency Cohort Study (CRIC): Overview and Summary of Selected Findings.The frequency of hyperkalemia and its significance in chronic kidney disease.Genotype-based changes in serum uric acid affect blood pressure.A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease.Patient-Reported Safety Events in Chronic Kidney Disease Recorded With an Interactive Voice-Inquiry Dial-Response System: Monthly Report Analysis.CKD as an underrecognized threat to patient safety.Frequency of hypoglycemia and its significance in chronic kidney disease.Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.Directed use of the internet for health information by patients with chronic kidney disease: prospective cohort study.Consideration of ICD-9 code-derived disease-specific safety indicators in CKD.Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney diseaseAssociation of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.Vascular access hemorrhages contribute to deaths among hemodialysis patients.Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease.Red blood cell transfusion, hyperkalemia, and heart failure in advanced chronic kidney disease.Renal function, erythropoietin, and anemia of older persons: the InCHIANTI study.Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections.The Effect of Universal Glove and Gown Use on Adverse Events in Intensive Care Unit Patients.Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
P50
Q28202746-9EBB1E58-A0C1-4B85-8614-73BC45C2DF6EQ33348175-CD3B226D-1F9E-4E90-BD53-ACA17A862A08Q33444517-48A2788F-BF67-4AF1-94E7-43241C3056DEQ33571370-B5B8084B-71C3-453B-A6CC-213F57A9837BQ33814930-093127D2-06AF-4B7A-8245-9344C6DF6089Q33827406-21838562-A02F-4C5E-A7F7-1A713F6AADF1Q33835766-FD4C4565-1EC3-4546-B891-E3FD0C28FA81Q34239669-55C57644-3211-4FC2-860F-7F18BD28A01DQ34299701-8266506C-C75C-4D3B-9020-BC4855B01FB5Q34309500-DF6EF90D-8822-4DC1-B951-57E0045FB371Q34383679-9A603E15-F768-4A95-B488-364D947935CEQ34751900-D19F7F9F-7F99-4E91-95A4-41D0587E62A6Q34985147-9AC4A801-6815-4A46-A641-0A06B39BDC6EQ35144435-0E4E4056-AE61-489D-8988-9CA52DC7E120Q35267152-30AB8894-CD23-48B6-9B0D-F2D1153A2CFCQ35460057-13757F84-2173-4D71-AEE8-B9B2E958782CQ35536642-330B9AD5-5EA0-40E4-A4FD-0A62201718D0Q35664862-E92D355A-F782-4CC3-B707-F9606DF0831AQ35789334-9948FC6E-AEF9-4411-A3D3-7D88D861BECAQ35798287-9F25C3E5-01F8-4D9D-BBA7-3EF6B4291667Q36032998-9DE12741-D9C6-40B8-995D-2E55A46F59CDQ36250305-F0ABA6B2-5283-4C6D-88D4-56EB8406E59CQ36530203-42D5C5B0-8BEC-4755-919B-A2A58685584CQ36808243-D01BD3FA-46DB-45B4-930E-E99078A69827Q36843484-A83306B7-8C5A-4F2B-B10D-5F430F3F35E9Q36990382-44E584D9-D8C3-48FE-AFAA-7231ED9E26D9Q37009412-BE03B3DE-16C4-4CA3-B3E3-8DA15531EE0AQ37211078-414E9EFA-9557-4877-8170-1D6E40AA9A46Q37297615-3374315C-B2CF-42C8-BF71-A5BFF3DC275BQ37344930-8AB28E1D-D10B-4637-AB90-889B3CE8AEE2Q37359101-BF2BAF79-5351-44B2-B407-E1F0D82F6762Q37438625-0E663E18-010B-4C0A-8ACC-9E8CFC67C956Q37625225-797871CD-8ED3-4770-9095-06879065BE6FQ38018463-46E0BADE-0FCD-49A1-ABB4-39834DC768C8Q38199563-02873485-0008-4729-AABE-C7D5097D09BEQ38436060-56D8DFF0-8EFB-4BB2-AB91-7B21F60E6BEFQ39734183-9E41AE57-AFEE-454B-8793-BD9D7DD1EE15Q40270951-74066F05-47D3-4C2A-8FC5-770CDEAD2719Q41299377-727C0E35-8B7D-4A77-9CA2-B850A21886A4Q43548938-C4BBFA1F-2073-4597-A891-2A8C4DA47937
P50
description
American nephrologist, university professor
@en
Amerikalı nefrolog uzmanı, üniversite profesörü
@tr
amerikai nefrológus, egyetemi tanár
@hu
onderzoeker
@nl
name
Jeffrey C Fink
@de
Jeffrey C Fink
@hu
Jeffrey C Fink
@tr
Jeffrey C. Fink
@en
Jeffrey C. Fink
@es
Jeffrey C. Fink
@sl
type
label
Jeffrey C Fink
@de
Jeffrey C Fink
@hu
Jeffrey C Fink
@tr
Jeffrey C. Fink
@en
Jeffrey C. Fink
@es
Jeffrey C. Fink
@sl
altLabel
Fink
@hu
prefLabel
Jeffrey C Fink
@de
Jeffrey C Fink
@hu
Jeffrey C Fink
@tr
Jeffrey C. Fink
@en
Jeffrey C. Fink
@es
Jeffrey C. Fink
@sl
P106
P1153
7403300505
P21
P31
P496
0000-0002-5622-5052